Fontan术后华法林与阿司匹林长期结局比较
该多中心研究比较澳大利亚和新西兰Fontan循环患者接受华法林或阿司匹林长期血栓预防的结局。结果显示脑血管损伤在两组均常见,华法林组出血更频繁且骨密度更低,生活质量两组相似,长期华法林未显示优于阿司匹林。
要点
- Fontan患者脑血管损伤常见,与抗凝药物类型无关
- 华法林组出血更频繁,骨密度更低
- 长期华法林预防未优于阿司匹林
核心结论
- 在澳大利亚和新西兰Fontan人群中,无论使用华法林还是阿司匹林,脑血管损伤均频繁发生。
- 长期华法林预防未显示出优于阿司匹林的获益。
- 华法林组出血更频繁且骨密度更低,需关注心脏和肺功能等临床特征。
研究设计与样本
- 多中心研究,选取澳大利亚和新西兰Fontan人群队列。
- 参与者接受脑磁共振成像检测脑血管损伤(n=84)和双能X线吸收测定评估骨密度(n=120)。
- 使用验证问卷评估出血(n=100)和生活质量(n=90)。
主要发现
- 33名参与者(39%)检测到卒中,其中仅7名(6%)有临床症状。
- 卒中与Fontan类型或血栓预防类型无关联。
- 大多数参与者检测到微出血(96%)和白质损伤(86%),与血栓预防类型无关。
- 两组出血率均高,但华法林组出血更频繁。
- 与一般人群相比,队列骨密度降低,华法林组进一步降低;生活质量两组相似。
临床怎么用
- Fontan术后长期血栓预防选择需权衡出血与骨密度风险,华法林未显示优于阿司匹林。
- 华法林组家庭INR监测与更好的生活质量评分相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Because of the nature of the Fontan physiology, patients are at an increased risk of thromboembolic complications. As such, warfarin or aspirin is generally prescribed lifelong for thromboprophylaxis. This study aimed to compare long-term rates of cerebrovascular injury, thrombosis, bleeding, bone mineral density, and quality of life in people living with Fontan circulation receiving warfarin compared with aspirin. METHODS: This was a multicenter study of a selected cohort from the Australia and New Zealand Fontan population. Participants underwent cerebral magnetic resonance imaging to detect the presence of cerebrovascular injury (n = 84) and dual-energy X-ray absorptiometry to assess bone mineral density (n = 120). Bleeding (n = 100) and quality of life (n = 90) were assessed using validated questionnaires: Warfarin and Aspirin Bleeding assessment tool and Pediatric Quality of Life Inventory, respectively. RESULTS: Stroke was detected in 33 participants (39%), with only 7 (6%) being clinically symptomatic. There was no association between stroke and Fontan type or thromboprophylaxis type. Microhemorrhage and white matter injury were detected in most participants (96% and 86%, respectively), regardless of thromboprophylaxis type. Bleeding rates were high in both groups; however, bleeding was more frequent in the warfarin group. Bone mineral density was reduced in our cohort compared with the general population; however, this was further attenuated in the warfarin group. Quality of life was similar between the warfarin and aspirin groups. Home international normalized ratio monitoring was associated with better quality of life scores in the warfarin group. CONCLUSIONS: Cerebrovascular injury is a frequent occurrence in the Australia and New Zealand Fontan population regardless of thromboprophylaxis type. No benefit of long-term warfarin prophylaxis could be demonstrated over aspirin; however, consideration must be given to important clinical features such as cardiac function and lung function. Furthermore, the association of reduced bone health in children receiving warfarin warrants further mechanistic studies.
引用
- Attard C, Monagle PT, d'Udekem Y, et al. Long-term outcomes of warfarin versus aspirin after Fontan surgery. J Thorac Cardiovasc Surg. 2021. PMID: 33563422. doi:10.1016/j.jtcvs.2020.12.102
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。